AU2019255611A1 - Glucose-responsive insulin - Google Patents

Glucose-responsive insulin Download PDF

Info

Publication number
AU2019255611A1
AU2019255611A1 AU2019255611A AU2019255611A AU2019255611A1 AU 2019255611 A1 AU2019255611 A1 AU 2019255611A1 AU 2019255611 A AU2019255611 A AU 2019255611A AU 2019255611 A AU2019255611 A AU 2019255611A AU 2019255611 A1 AU2019255611 A1 AU 2019255611A1
Authority
AU
Australia
Prior art keywords
peptide
insulin
chain
seq
chain peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019255611A
Other languages
English (en)
Inventor
Danny Hung-Chieh Chou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU2019255611A1 publication Critical patent/AU2019255611A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019255611A 2018-04-16 2019-04-15 Glucose-responsive insulin Abandoned AU2019255611A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (1)

Publication Number Publication Date
AU2019255611A1 true AU2019255611A1 (en) 2020-11-12

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019255611A Abandoned AU2019255611A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Country Status (8)

Country Link
US (1) US20210214412A1 (https=)
EP (1) EP3781147A4 (https=)
JP (1) JP2021521230A (https=)
KR (1) KR20210005630A (https=)
CN (1) CN112423741A (https=)
AU (1) AU2019255611A1 (https=)
CA (1) CA3097359A1 (https=)
WO (1) WO2019204206A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016179568A1 (en) 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins
EP3939605A1 (en) 2016-12-09 2022-01-19 Akston Biosciences Corporation Insulin-fc fusions and methods of use
WO2019092125A1 (en) 2017-11-09 2019-05-16 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
EP3946363A2 (en) * 2019-03-29 2022-02-09 Novo Nordisk A/S Glucose sensitive insulin derivatives
JP7834341B2 (ja) * 2019-07-31 2026-03-24 シーエス ファーマシューティカルズ エルエルシー グルコース調節型立体配座スイッチを有するインスリン類似体
FI4073098T3 (fi) 2019-12-19 2023-11-15 Akston Biosciences Corp Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
EP4126058A1 (en) * 2020-03-31 2023-02-08 Protomer Technologies Inc. Conjugates for selective responsiveness to vicinal diols
CN116096733A (zh) 2020-04-10 2023-05-09 阿卡斯通生物科学公司 Covid-19融合蛋白的抗原特异性免疫疗法和使用方法
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
JP2024500284A (ja) * 2020-11-19 2024-01-09 プロトマー・テクノロジーズ・インコーポレイテッド 芳香族ホウ素含有化合物及びインスリン類似体
US11667689B2 (en) 2021-07-23 2023-06-06 Akston Biosciences Corporation Insulin-Fc fusion proteins and methods of use to treat cancer
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン60.1由来のペプチドを作製する方法
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体,その製法,及びヒト型インシュリンの製造法
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
EP1453860A2 (en) * 2001-12-02 2004-09-08 Novo Nordisk A/S Novel glucose-dependant insulins
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
US7928186B2 (en) * 2006-08-02 2011-04-19 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
CN102770153B (zh) * 2010-02-22 2014-05-07 卡斯西部储备大学 呈可溶和结晶形式的长效胰岛素类似物制剂
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
WO2014093696A2 (en) * 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2016179568A1 (en) * 2015-05-06 2016-11-10 Protomer Technologies, Inc. Glucose responsive insulins

Also Published As

Publication number Publication date
US20210214412A1 (en) 2021-07-15
WO2019204206A1 (en) 2019-10-24
EP3781147A1 (en) 2021-02-24
CA3097359A1 (en) 2019-10-24
EP3781147A4 (en) 2022-04-20
CN112423741A (zh) 2021-02-26
JP2021521230A (ja) 2021-08-26
KR20210005630A (ko) 2021-01-14

Similar Documents

Publication Publication Date Title
US20210214412A1 (en) Glucose-responsive insulin
TWI910174B (zh) Glp-1和gip受體雙重激動劑化合物及其應用
ES2238641T3 (es) Tiazolididas y pirrolididas de glutamina, asi como su utilizacion como agentes inhibidores de la dipeptidilpeptidasa iv.
EP3034090B1 (en) Stable insulin secretagogue peptide hydro-injection pharmaceutical composition
US11155577B2 (en) Thiol-ene based peptide stapling and uses thereof
JP2009521441A (ja) ソフトプロテアーゼ抑制剤およびそのプロソフト型
KR20180128945A (ko) 고 m6p 재조합 단백질의 선택 방법
EP4442700A1 (en) Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
EP4431522A1 (en) Pharmaceutical composition of glp-1 receptor and gip receptor dual agonist, and use thereof
TWI672315B (zh) 醯化之胰島素化合物
US20240041982A1 (en) Extended release hydrogel conjugates of c-natriuretic peptides
US11413352B2 (en) Conjugate based systems for controlled insulin delivery
US11034720B2 (en) Thiol-yne based peptide stapling and uses thereof
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
TW202409070A (zh) 芳族含硼化合物及相關胰島素類似物
CN105985425B (zh) 一种聚乙二醇修饰的exendin类似物及其制备方法和应用
JP6005732B2 (ja) 非ペプチド性重合体−インスリン多量体及びその製造方法
JP2008531482A (ja) C末端がpeg化された成長ホルモン
WO2017212494A1 (en) Long-acting oxyntomodulin formulation and methods of producing and administering same
US20250186538A1 (en) Bivalirudin compounds
CN116917297A (zh) 芳香族含硼化合物和胰岛素类似物
EP4722236A1 (en) Insulin derivative and use thereof
BR112019021668B1 (pt) Composto acilado de insulina, uso do mesmo, e composição farmacêutica que o compreende
BR112018070189B1 (pt) Método para seleção de proteínas recombinantes ricas em m6p
BR122022003324B1 (pt) Composições de hormônio do crescimento

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application